NCT06890169 OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
| NCT ID | NCT06890169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Changi General Hospital |
| Condition | Obesity and Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-05-01 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). Researchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care. Participants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. Participants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.
Eligibility Criteria
Inclusion Criteria: * Adults aged 21-70 * Body mass index \> 27.5 kg/m2 * Waist circumference \> 90 cm in men or 80 cm in women * Suboptimal control of type 2 diabetes (HbA1c \> 6.5%) AND/OR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease) Exclusion Criteria: * Men who drink \> 21 units/week and women who drink \> 14 units/week of alcohol * Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation) * Illness with life expectancy of less than 6 months * Inability to comply with written instructions in English
Contact & Investigator
Joan Khoo, MBBS, FRCP
PRINCIPAL INVESTIGATOR
Changi General Hospital
Frequently Asked Questions
Who can join the NCT06890169 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Obesity and Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06890169 currently recruiting?
Yes, NCT06890169 is actively recruiting participants. Contact the research team at joan.khoo.j.c@singhealth.com.sg for enrollment information.
Where is the NCT06890169 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06890169 clinical trial?
NCT06890169 is sponsored by Changi General Hospital. The principal investigator is Joan Khoo, MBBS, FRCP at Changi General Hospital. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.